<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638780</url>
  </required_header>
  <id_info>
    <org_study_id>11-3-092</org_study_id>
    <nct_id>NCT01638780</nct_id>
  </id_info>
  <brief_title>Resveratrol and Type 2 Diabetes</brief_title>
  <official_title>Effect of Resveratrol on Insulin Sensitivity and Metabolic Profile in Type 2 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to investigate if resveratrol supplementation can improve
      overall and muscle-specific insulin sensitivity in type 2 diabetic patients.

      As a secondary objective the investigators want to investigate whether the improved insulin
      sensitivity can be attributed to improved muscle mitochondrial oxidative capacity and a
      reduced intrahepatic and cardiac lipid content.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity (overall, muscle- and liver specific)</measure>
    <time_frame>30 days after supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle mitochondrial oxidative capacity</measure>
    <time_frame>30 days after supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intramyocellular lipid content</measure>
    <time_frame>30 days after supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intrahepatic lipid content</measure>
    <time_frame>30 days after supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracardiac lipid content</measure>
    <time_frame>30 days after supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart function</measure>
    <time_frame>30 days after supplementation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>resveratrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>resveratrol</intervention_name>
    <description>resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.</description>
    <arm_group_label>resveratrol</arm_group_label>
    <other_name>resVida (99% pure trans-resveratrol) provided by DSM Nutritional Products, Ltd.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex

          -  Age: 40-70 years

          -  Body fat percentage &gt; 25, BMI 27-35 kg/m2

          -  Diagnosed with type 2 diabetes at least one year before the start of the study

          -  Well-controlled type 2 diabetics: HBA1C &lt; 8.0%

          -  Oral glucose lowering medication (metformin only or in combination with sulfonylurea
             agents)

          -  Sedentary

               -  Not more than 2 hours of sports a week

               -  No active job that requires strenuous physical activity

          -  Stable dietary habits

          -  Willingness to abstain from resveratrol-containing food products

        Exclusion Criteria:

          -  Unstable body weight (weight gain or loss &gt; 3kg in the last three months)

          -  Total body fat percentage &lt; 25%

          -  Hemoglobin &lt; 7.8 mmol/l

          -  Use of anticoagulants

          -  Engagement in programmed exercise &gt; 2 hours total per week

          -  Impaired kidney and/or hepatic function Creatinine 50-100 umol/L Liver enzymes, within
             2 times of normal range of laboratory standard (ASAT &lt; 60 U/L, ALAT &lt; 70 U/L, Billi
             &lt;40 umol/L, gamma-GT &lt; 80 U/L)

          -  No diabetes related co-morbidities like cardiovascular diseases, diabetic foot,
             polyneuropathy, retinopathy

          -  Insulin dependent Diabetic subjects

          -  Any medical condition except type 2 diabetes mellitus requiring treatment and/or
             medication use except metformin only or in combination with sulfonylurea agents

          -  Intake of dietary supplements except multivitamins and minerals

          -  Current alcohol consumption &gt; 20 grams/day

          -  Subjects who don't want to be informed about unexpected medical findings during the
             screening /study, or do not wish that their physician is informed, cannot participate
             in the study.

          -  Participation in another biomedical study within 1 month before the first screening
             visit

          -  Any contraindication to MRI scanning. These contra-indications include patients with
             following devices:

               -  Central nervous system aneurysm clip

               -  Implanted neural stimulator

               -  Implanted cardiac pacemaker of defibrillator

               -  Cochlear implant

               -  Insulin pump

               -  Or metal containing corpora aliena in the eye or brains
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvie Timmers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Human Biology, Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov 2;14(5):612-22. doi: 10.1016/j.cmet.2011.10.002.</citation>
    <PMID>22055504</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

